エピソード

  • Post-Traumatic Headache in Children and Genetic Risk of Migraine
    2026/08/13

    Dr. Jessica Ailani and Dr. Serena Orr discuss the genetic risk of migraine and post-traumatic headache in children.

    Show citation:

    Orr SL, Hershey AD, Kurowski BG, et al. Post-Traumatic Headache in Children and Genetic Risk of Migraine: An Observational Cohort Study. Neurol Genet. 2026;12(2):e200371. Published 2026 Apr 1. doi:10.1212/NXG.0000000000200371

    続きを読む 一部表示
    2 分
  • Efficacy and Safety of Cemdisiran siRNA in Myasthenia Gravis
    2026/08/12

    Dr. Aaron S. Zelikovich discusses the phase 3 NIMBLE trial of cemdisiran, an siRNA targeting complement component 5, for the treatment of generalized myasthenia gravis.

    Show citation:

    Vu T, Habib AA, Jacob S, et al. Efficacy and safety of cemdisiran siRNA in myasthenia gravis (NIMBLE): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet. 2026;407(10540):1712-1725. doi:10.1016/S0140-6736(26)00690-2

    続きを読む 一部表示
    3 分
  • Negative Myoclonus
    2026/08/11

    Dr. Zohaib Siddiqi shares clinical pearls on negative myoclonus.

    続きを読む 一部表示
    3 分
  • An Update on Troriluzole
    2026/08/10

    Dr. Margarita Fedorova discusses the use of troriluzole for spinocerebellar ataxia.

    Show citations:

    https://www.neurology.org/doi/10.1212/WNL.0000000000209018

    https://clinicaltrials.gov/study/NCT06034886

    https://clinicaltrials.gov/study/NCT02960893

    続きを読む 一部表示
    4 分
  • The Current State of Diagnostics for Neuroimmunologic Disorders in Africa
    2026/08/07

    Drs. Paul Crane, Fiifi Duodu, and Malya Sahu discuss neuroimmunology and multiple sclerosis diagnosis in Africa, including challenges and efforts to improve care.

    Show citation:

    Sahu M, Chomba M, Duodu F, Diaz MM, Sokhi D, Saylor D. The Current State of Diagnostics for Neuroimmunological Disorders in Africa. J Cent Nerv Syst Dis. 2025;17:11795735251385319. Published 2025 Nov 19. doi:10.1177/11795735251385319

    続きを読む 一部表示
    3 分
  • Ampreloxetine for Neurogenic Orthostatic Hypotension in MSA
    2026/08/06

    Dr. Elizabeth Coon and Dr. Lucy Norcliffe-Kaufmann discuss the mechanism-based therapy with ampreloxetine for neurogenic orthostatic hypotension in multiple system atrophy, highlighting recent clinical trial results and future directions.

    Show citation:

    Freeman R, Kaufmann H, Biaggioni I, et al. Mechanism-Based Therapy With Ampreloxetine for Neurogenic Orthostatic Hypotension in Multiple System Atrophy: A Randomized Withdrawal Trial. Neurology. 2026;107(3):e218284. doi:10.1212/WNL.0000000000218284

    続きを読む 一部表示
    4 分
  • Sex Differences in Levodopa Pharmacokinetics in Early Parkinson Disease
    2026/08/05

    Dr. Margarita Fedorova explores sex-related differences in the pharmacokinetics of levodopa among levodopa-naïve patients with PD and evaluates their relationships with levodopa-related complications.

    Show citation:

    Conti V, De Bellis E, Corbi G, et al. Sex differences in levodopa pharmacokinetics in early Parkinson's disease: implications on levodopa-related complications. Front Pharmacol. 2026;17:1748932. Published 2026 Apr 7. doi:10.3389/fphar.2026.1748932

    続きを読む 一部表示
    3 分
  • Psychiatric Comorbidities in Epilepsy - Part 2
    2026/08/04

    In part two of this series, Dr. Halley Alexander and Dr. Heidi Munger Clary discuss the steps to take if you are screening for a psychiatric comorbidity and the results indicate that someone may be positive for depression, anxiety, or another condition.

    Show citations:

    Mula M, Brodie MJ, de Toffol B, et al. ILAE clinical practice recommendations for the medical treatment of depression in adults with epilepsy. Epilepsia. 2022;63(2):316-334. doi:10.1111/epi.17140

    Patel AD, Baca C, Franklin G, et al. Quality improvement in neurology: Epilepsy Quality Measurement Set 2017 update. Neurology. 2018;91(18):829-836. doi:10.1212/WNL.0000000000006425

    続きを読む 一部表示
    4 分